The COCOON dermatologic administration routine decreased QOL influence of Rybrevant/Lazcluze vs SOC in EGFR-mutated NSCLC: © inventory.adobe.com.
The COCOON dermatologic administration routine considerably decreased the quality-of-life influence related to Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) remedy versus the standard-of-care dermatologic administration method in sufferers with EGFR-mutated non-small cell lung most cancers (NSCLC), in keeping with part 2 findings from the COCOON trial, which had been shared on the 2025 ASCO Annual Assembly.
A decrease common Skindex-16 complete rating was reported in sufferers who acquired COCOON DM versus these with standard-of-care dermatologic administration at day 15 of cycle three. Moreover, use of COCOON DM correlated with enhancements within the functioning, emotional and signs subscales.
No reasonable or extreme signs on the Affected person International Impression of Severity (PGI-S) scale occurred amongst sufferers who acquired COCOON DM at day 15 of cycle three. The charges of sufferers reporting no signs within the COCOON DM and standard-of-care dermatologic administration arms, respectively, had been 21% versus 7% for rash, 23% versus 7% for pores and skin situations and 27% versus 16% for nail infections.
“At this evaluation, which evaluated the primary 12 weeks of remedy, [patients] within the COCOON DM arm skilled decrease severity of dermatologic signs and a minimal impact on high quality of life than [patients] within the standard-of-care dermatologic administration arm,” lead examine writer Jill Feldman, founding father of EGFR Registers, a affected person advocacy group in Deerfield, Illinois, wrote with coauthors. “Substantial and constant separation favoring COCCON DM was noticed in all postbaseline Skindex-16 subscales. Most [patients] within the COCOON DM arm reported gentle or no dermatologic signs. This profit was constantly noticed throughout the primary [approximately] 10 weeks of remedy.”
Investigators of the part 2 COCOON trial prospectively assessed a novel DM routine for stopping reasonable to extreme EGFR-associated unintended effects which will happen following remedy with amivantamab plus lazertinib. On this evaluation, investigators highlighted patient-reported outcomes from the primary 12 weeks of remedy.
A complete of 201 sufferers had been randomly assigned to obtain amivantamab/lazertinib plus COCOON DM (99 sufferers) or standard-of-care dermatologic administration (102 sufferers). The COCOON routine consisted of oral doxycycline or minocycline for 12 weeks adopted by topical clindamycin lotion every day on the scalp, beginning at week 13 for 9 months; chlorhexidine on the nails every day for 12 months; and ceramide-based moisturizer utilized to the physique and face not less than every day for 12 months. Within the standard-of-care dermatologic administration arm, sufferers acquired basic pores and skin prophylaxis based mostly on native apply and relative remedy, together with corticosteroids and systemic antibiotics.
The examine’s major finish level was the incidence of grade 2 or increased dermatologic unintended effects throughout the first 12 weeks following the start of amivantamab/lazertinib remedy. The choose secondary finish factors had been PROs per Skindex-16 and PGI-S after 12 weeks of follow-up.
The Skindex-16 questionnaire was validated to find out how pores and skin situations influence high quality of life based mostly on the subscales of functioning, emotional, and signs. The PGI-S was a patient-reported 4-point ranking scale — none, gentle, reasonable, or extreme signs — used to judge the severity of rashes, pores and skin situations, and nail infections over time.
These with domestically superior or metastatic, treatment-naïve NSCLC harboring documented EGFR exon 19 deletions or L858R mutations had been eligible for enrollment on the examine. An ECOG efficiency standing of 0 or 1 was an extra requirement for examine entry.
The investigators famous that the FDA authorized amivantamab/lazertinib for sufferers with domestically superior or metastatic EGFR–mutated NSCLC based mostly on findings from the part 3 MARIPOSA trial.
Reference
Feldman J, et al. “Dermatologic prophylaxis and influence on patient-reported outcomes in first-line EGFR-mutant superior NSCLC handled with amivantamab plus lazertinib: Outcomes from the part 2 COCOON trial.” J Clin Oncol. 2025;43(suppl 16):8641. doi:10.1200/JCO.2025.43.16_suppl.8641
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
